Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia 1

Interventions

Cyclophosphamide 59fludarabine phosphate 53Peripheral Blood Stem Cell Transplantation 43Tacrolimus 40Mycophenolic Acid 36Busulfan 33Whole-Body Irradiation 32Antilymphocyte Serum 28Cyclosporine 27Methotrexate 25fludarabine 19Filgrastim 18Melphalan 17Radiotherapy 15Methylprednisolone 13Etoposide 12Cord Blood Stem Cell Transplantation 12thymoglobulin 11Sirolimus 11ruxolitinib 10Flow Cytometry 10Psychiatric Rehabilitation 9Azacitidine 9Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Decitabine 7Therapeutics 6Imatinib Mesylate 6Cytarabine 6Cyclosporins 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × KB004 × Other hematologic neoplasm × Clear all
NCT01211691 2015-11-17

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Humanigen, Inc.

Phase 1/2 Suspended
120 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡